![]() The Pfizer-BioNTech, Moderna, and Johnson & Johnson vaccines are all being administered in the United States, but whereas the Johnson & Johnson vaccine only requires one shot for immunization, the Pfizer-BioNTech and Moderna vaccines each require two doses, administered several weeks apart. However, she cautioned that people, particularly older people, must remember that they're not fully protected against COVID-19 during the period between doses.Three different COVID-19 vaccines are authorized for use in the U.S., with two of these requiring the administration of two doses. "I feel strongly that the Canadian strategy which prioritized a single shot into as many people as possible has saved an inordinate number of lives," Kelvin said in an email to CBC News. ![]() ![]() Prof. Alyson Kelvin, a virologist at Dalhousie University and the IWK Health Centre in Halifax, agreed that the British study results support Canada's dose-spacing strategy. "In fact, we anticipated that the boost response would be improved by that extended interval." "We underscored that extending the interval between first and second doses would enable more people to benefit from the substantial protection offered by a single dose without negatively affecting the second dose boost response," Skowronski said. Danuta Skowronski of the BC Centre for Disease Control, whose research helped guide Canada's decision to extend the interval between COVID-19 vaccine shots, in an email to CBC News. "The findings are not a surprise," said Dr. 'Not a surprise,' Canadian vaccine expert saysĮxperts in Canada said the British findings show that a fundamental principle of how vaccines traditionally work appears to apply in mRNA vaccines like Pfizer-BioNTech. for delaying that second dose has really paid off," Gayatri Amirthalingam, consultant epidemiologist at Public Health England, told reporters. However, taken with data showing good protection against hospitalization and death from just one shot of Pfizer vaccine, Public Health England said the study was further supportive evidence in favour of the delayed-dose approach. The authors warned against drawing conclusions on how protected individuals were based on which dosing schedule they received. ![]() The study, which has not yet been peer-reviewed, looked at 175 people aged between 80 and 99, and found that extending the second dose interval to 12 weeks increased the peak antibody response 3.5-fold compared to those who had it at three weeks.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |